PRME: Prime Medicine, Inc.
Performance
PRME +12.86%
Watchlist
Select an item
Summary
PRME at a glance
PRME returned +12.86% over the past year. Its worst drop in that year was -42.25%, smaller than 34% of stocks on Redstone, and its Sharpe ratio of 0.54 beats 53% of stocks on Redstone. It pays no dividends.
Current Drawdown
-19.78%
Rolling Volatility
152.24%
Actions
Metrics
Risk Indicators
Alpha27.14%
Beta2.27x
Sharpe0.54
Sortino0.89
Omega1.09
Calmar0.30
Martin2.01
Profile
About PRME
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression.
- Sector
- Health Care
- Industry
- Biological Products, (no Diagnostic Substances)
- Market cap
- $780M
- Listed
- Oct 2022
- Employees
- 146
- Headquarters
- Cambridge, MA
- Website
- primemedicine.com
Comparisons